arrow
A

Alessandro Tavelli

Icona Foundation
H指数:17
被引数:1,672

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trends in Hepatitis D Virus Prevalence Among HBsAg-Positive Individuals With and Without HIV in Italy: A Converging Epidemiology

意大利HBsAg阳性个体中伴有与不伴有HIV的丁型肝炎病毒流行趋势:一种趋同的流行病学

2026-10-070
PRE
Virological outcomes of PWH who discontinued cabotegravir/rilpivirine long-acting therapy in a real-world context

HIV感染者中停用卡博特韦/利匹韦林长效疗法后的病毒学结局

2026-04-150
OAAI
Implementing the National Vaccination Plan in people with HIV in Italy: A survey among ICONA centres

在意大利HIV感染者中实施国家疫苗接种计划:ICONA中心调查

2026-04-010
PRE
Implementation of HIV Pre-exposure Prophylaxis (PrEP) in Italy (2023–2024): Results from the PrIDE Cohort Survey

意大利艾滋病病毒暴露前预防(PrEP)的实施(2023–2024年):PrIDE队列调查结果

2026-03-150
OAAI
Peer-supported digital collection of patient-reported outcomes in HIV care: Promise, practical barriers and lessons from a pilot study within the ICONA cohort

同伴支持下的数字患者报告结局在HIV护理中的应用:前景、实际障碍及ICONA队列内试点研究的经验教训

2026-02-250
PRE
HIV INFECTION AMONG ADOLESCENTS AND YOUNG ADULTS IN ITALY: EPIDEMIOLOGY, VIRO-IMMUNOLOGICAL AND TREATMENT OUTCOMES

意大利青少年和年轻成人中的HIV感染:流行病学、病毒-免疫学及治疗效果

2025-11-150
OAAI
Long-term trajectories of Hepatic and Metabolic biomarkers after switching from TDF to TAF in ART-Experienced PWH with and without Hepatic Coinfection: Data from the ICONA Cohort

从TDF转换为TAF后,在伴有和不伴有肝共感染的经治人类免疫缺陷病毒感染者中,肝脏和代谢生物标志物的长期变化轨迹:ICONA队列研究数据

2025-10-040
OAAI
Incidence, risk factors and outcomes of healthcare-associated bacterial infections in COVID-19 patients receiving respiratory support: a retrospective cohort study

新型冠状病毒肺炎患者接受呼吸支持治疗中,医院获得性细菌感染的发病率、危险因素及结局:一项回顾性队列研究

2025-09-050
OAAI
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort

HIV感染者中一线拉米夫定/多替拉韦抗逆转录病毒疗法的有效性:ICONA基金会队列的真实世界数据

2025-09-010
PRE
HIV Oral Pre-exposure Prophylaxis Effectiveness, Adherence, and Discontinuation in an Italian Multicentric Access Program: ItaPrEP Study

HIV口腔前暴露预防效果、依从性及停药情况在意大利多中心获取计划中的研究:ItaPrEP研究

2025-09-013
OAAI
All-cause and Cause-specific Mortality in People With HIV in Italy in 1997-2022: Data From the Icona Cohort

1997-2022年意大利HIV感染者全因和特定原因死亡率:Icona队列研究数据

2025-08-010
OAAI
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation

病毒学抑制的HIV感染者转换为双药方案与维持三药方案的临朐事件风险:目标试验模拟

2025-07-240
OA
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: A trial emulation

达芦那韦组与利托那韦增强型达芦那韦组在晚期HIV患者中的三联一线方案有效性比较:一项试验模拟研究

2025-06-010
OAAI
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort

长效卡博特格拉韦/利匹韦林治疗中断的有效性及预测因素:来自Icona队列的真实世界数据,用于研究病毒学受抑制的HIV感染者

2025-06-011
PRE
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy

选定的合并症及HIV-RNA检测不到的PWH中ART转换的概率:意大利的一项回顾性分析

2025-05-120
OA
Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort

在HIV感染者中,从双重疗法转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺的安全性及有效性:ICONA队列研究的启示

2025-04-280
OAAI
Role of low-frequency integrase strand transfer inhibitor resistance mutations on virological outcomes in antiretroviral therapy-naïve individuals initiating second-generation integrase inhibitors

抗逆转录病毒治疗初治个体中,低频整合酶链转移抑制剂耐药突变对病毒学结局的影响

2025-04-100
OA
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV

ORCHESTRA Delphi共识:人类免疫缺陷病毒感染者中严重急性呼吸综合征冠状病毒2型感染的临床管理

2025-03-210
PRE
ORCHESTRA Delphi consensus: diagnostic and therapeutic management of SARS-CoV-2 infection in solid organ transplant recipients

ORCHESTRA 德尔菲共识:实体器官移植受者SARS-CoV-2感染的诊断与治疗管理

2025-02-130
PRE